Our analysis of February data reveals key trends in global preclinical-stage biopharmaceutical financing.

As global healthcare continues to demand innovative therapies, February 2025 has emerged as a critical period witnessing the robust growth of the biopharmaceutical sector.

February 2025 brought a wave of exciting news for innovators in the global healthcare industry.

February 2025 witnessed a wave of mergers and acquisitions in the global biopharmaceutical sector.

In January 2025, the global pharmaceutical industry's investment and licensing activities demonstrated a strong interest in novel treatment methods and technologies.

In January 2025, the pharmaceutical collaborations and transactions showcased a diversified trend of development, ranging from multinational pharmaceutical corporations to startup biotech enterprises.

With the thriving development of the biopharmaceutical industry, January 2025 witnessed several significant financing events exceeding $100 million.

In January 2025, several companies announced collaborations with international pharmaceutical giants to launch a series of new drugs globally.

In January 2025, a series of collaborative agreements were successively reached in the field of antibody-based pharmaceuticals in China.

In January 2025, China’s innovative pharmaceutical sector continues to make its mark on the global stage.

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry.

10.28-11.3, Global Pharmaceutical Investment, Financing and Deal Events Summary.